[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Biopharma_Watch Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1734221906151165952.png) BiopharmaWatch [@Biopharma_Watch](/creator/twitter/Biopharma_Watch) on x XXX followers
Created: 2025-07-24 16:58:33 UTC

Sionna Therapeutics (NASDAQ: $SION) is making waves in a tough biotech IPO market.

The company just raised $219M in its IPO, targeting cystic fibrosis (CF) with a novel “undruggable” approach. Their therapies could restore near-normal CFTR function for over XX% of CF patients, addressing gaps left by current treatments.

Key points:

Positive Phase X data for lead candidates SION-719 and SION-451, with Phase 2a trials starting soon

Global CF therapy market projected to reach $39B by 2034

Strong cash runway through 2028, all analysts rate Sionna a “Buy”

Major milestone: mid-2026 clinical data readout

Sionna’s high-risk, high-reward profile and strong analyst backing make it one to watch.

Want more biotech IPO insights and real-time catalyst analysis?

👉 Visit

#Biotech #IPO #CysticFibrosis #SION #DrugDevelopment

![](https://pbs.twimg.com/media/Gwo0dTIaIAArpNF.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948427594489364784/c:line.svg)

**Related Topics**
[$219m](/topic/$219m)
[ipo](/topic/ipo)
[$sion](/topic/$sion)
[nasdaq](/topic/nasdaq)

[Post Link](https://x.com/Biopharma_Watch/status/1948427594489364784)